Volume 29, Issue 2 (June 2025)                   Physiol Pharmacol 2025, 29(2): 146-154 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nazari S, Gheibi M, Ghazvini H, Rafaiee R, Seyedhosseini Tamijani S M. Kisspeptin-13 attenuates the rewarding but not the reinstatement effects of methamphetamine in the conditioned place preference test in rats. Physiol Pharmacol 2025; 29 (2) :146-154
URL: http://ppj.phypha.ir/article-1-2316-en.html
Kisspeptin-13 attenuates the rewarding but not the reinstatement effects of methamphetamine in the conditioned place preference test in rats
Somayeh Nazari , Mobina Gheibi , Hamed Ghazvini , Raheleh Rafaiee , Seyedeh masoumeh Seyedhosseini Tamijani
Abstract:   (1021 Views)

Introduction: Methamphetamine (MA) addiction is a major global public health concern, yet there is currently no approved medication that effectively treats this addiction. Kisspeptin is a neuropeptide that has a role in the reproductive system, metabolism and energy balance, and metastasis suppression in different types of cancers. The kisspeptin receptors, GPR54 are widely distributed in the brain’s memory-related structures. Previous studies have revealed that the opioid system contributes to the addictive effects of MA. Additionally, preclinical studies have shown that a derivative of kisspeptin possesses anti-opioid properties. This study aimed to clarify the role of kisspeptin-13 (KP-13) on reward and reinstatement-related memory associated with MA in the conditioned place preference test.
Methods: We evaluated pre-treatment with intracerebroventricular KP-13 for 3 consecutive days (2.5 μl/nostril, once a day) in a conditioned place preference test induced by MA. MA was administered intraperitoneally at a dose ranging from 1 to 7 mg/kg, once daily, beginning at 1 mg/kg on day one and increasing by 1 mg/kg per day up to the day 7.
Results: We found that KP-13 suppresses the reward behavior in MA-treated rats, while it has no significant effect on reinstatement behavior after one week of MA cessation, which could be attributed to the ineffective dose of KP-13.
Conclusion: The findings indicate that KP-13 alters the rewarding and motivating effects of MA. Further research involving both multiple and single administrations of KP-13 before the reinstatement test is necessary to throw light on its impact on withdrawal-related reinstatement.

Keywords: Kisspeptin-13, Methamphetamine, Reward, Reinstatement, Condition place preference
Full-Text [PDF 482 kb]   (43 Downloads)    
Type of Manuscript: Experimental research article | Subject: Neurophysiology/Pharmacology
References
1. Anooshe M, Nouri K, Karimi-Haghighi S, Mousavi Z, Haghparast A. Cannabidiol efficiently suppressed the acquisition and expression of methamphetamine-induced conditioned place preference in the rat. Behavioural Brain Research 2021; 404: 113158. [DOI:10.1016/j.bbr.2021.113158]
2. Chiu C-T, Ma T, Ho I K. Methamphetamine-induced behavioral sensitization in mice: alterations in μ-opioid receptor. Journal of biomedical science 2006; 13: 797-811. [DOI:10.1007/s11373-006-9102-x]
3. Delmas S, Porteous R, Bergin D H, Herbison A E. Altered aspects of anxiety-related behavior in kisspeptin receptor-deleted male mice. Scientific Reports 2018; 8: 2794. [DOI:10.1038/s41598-018-21042-4]
4. Ebrahimi Z, Kahvandi N, Komaki A, Karimi S A, Naderishahab M, Sarihi A. The role of mGlu4 receptors within the nucleus accumbens in acquisition and expression of morphine-induced conditioned place preference in male rats. BMC neuroscience 2021; 22: 1-10. [DOI:10.1186/s12868-021-00627-2]
5. Ekhtiari H, Nasseri P, Yavari F, Mokri A, Monterosso J. Neuroscience of drug craving for addiction medicine: From circuits to therapies. Progress in brain research 2016; 223: 115-141. [DOI:10.1016/bs.pbr.2015.10.002]
6. Everitt B J. Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories-indications for novel treatments of addiction. Eur J Neurosci 2014; 40: 2163-2182. [DOI:10.1111/ejn.12644]
7. Gibula-Bruzda E, Marszalek-Grabska M, Gawel K, Trzcinska R, Silberring J, Kotlinska J H. The new kisspeptin derivative-kissorphin (KSO)-attenuates acute hyperlocomotion and sensitization induced by ethanol and morphine in mice. Alcohol 2017; 64: 45-53. [DOI:10.1016/j.alcohol.2017.04.005]
8. Gibula-Tarlowska E, Grochecki P, Silberring J, Kotlinska J H. The kisspeptin derivative kissorphin reduces the acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in rats. Alcohol 2019a; 81: 11-19. [DOI:10.1016/j.alcohol.2019.04.001]
9. Gibula-Tarlowska E, Kedzierska E, Piechura K, Silberring J, Kotlinska J. The influence of a new derivate of kisspeptin-10-Kissorphin (KSO) on the rewarding effects of morphine in the conditioned place preference (CPP) test in male rats. Behavioural Brain Research 2019b; 372: 112043. [DOI:10.1016/j.bbr.2019.112043]
10. Ibos K E, Bodnár É, Bagosi Z, Bozsó Z, Tóth G, Szabó G, et al. Kisspeptin-8 induces anxiety-like behavior and hypolocomotion by activating the HPA axis and increasing GABA release in the nucleus accumbens in rats. Biomedicines 2021; 9: 112. [DOI:10.3390/biomedicines9020112]
11. Jiang J, He Z, Peng Y, Jin W, Wang Z, Han R, et al. Kisspeptin-13 enhances memory and mitigates memory impairment induced by Aβ1-42 in mice novel object and object location recognition tasks. Neurobiology of learning and memory 2015; 123: 187-195. [DOI:10.1016/j.nlm.2015.05.010]
12. Khodamoradi M, Tirgar F, Ghazvini H, Rafaiee R, Tamijani S M S, Karimi N, et al. Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment. Neuroscience letters 2022; 779: 136634. [DOI:10.1016/j.neulet.2022.136634]
13. Khonacha S E, Janahmadi M, Motamedi F. Kisspeptin-13 improves spatial memory consolidation and retrieval against amyloid-β pathology. Iran J Pharm Res 2019; 18: 169.
14. Kotlinska J, Pachuta A, Dylag T, Silberring J. Neuropeptide FF (NPFF) reduces the expression of morphine-but not of ethanol-induced conditioned place preference in rats. Peptides 2007; 28: 2235-2242. [DOI:10.1016/j.peptides.2007.08.006]
15. Kotlinska J, Pachuta A, Silberring J. Neuropeptide FF (NPFF) reduces the expression of cocaine-induced conditioned place preference and cocaine-induced sensitization in animals. Peptides 2008; 29: 933-939. [DOI:10.1016/j.peptides.2008.01.008]
16. Lyubimov Y, Engstrom M, Wurster S, Savola J-M, Korpi E, Panula P. Human kisspeptins activate neuropeptide FF2 receptor. Neuroscience 2010; 170: 117-122. [DOI:10.1016/j.neuroscience.2010.06.058]
17. Magendzo K, Bustos G. Expression of amphetamine-induced behavioral sensitization after short-and long-term withdrawal periods: Participation of μ-and δ-opioid receptors. Neuropsychopharmacology 2003; 28: 468-477. [DOI:10.1038/sj.npp.1300063]
18. Malin D H, Lake J R, Fowler D E, Hammond M V, Brown S L, Leyva J E, et al. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 1990; 11: 277-280. [DOI:10.1016/0196-9781(90)90082-G]
19. Melka N, Pszczolinska A, Klejbor I, Ludkiewicz B, Kowiański P, Moryś J. Can the kisspeptin help us in the understanding of pathology of some neurodegenerative brain diseases? Folia Morphologica 2021; 80: 756-765. [DOI:10.5603/FM.a2021.0090]
20. Mills E G, Dhillo W S, Comninos A N. Kisspeptin and the control of emotions, mood and reproductive behaviour. Journal of Endocrinology 2018; 239: R1-R12. [DOI:10.1530/JOE-18-0269]
21. Mills E G, O’Byrne K T, Comninos A N. Kisspeptin as a behavioral hormone. Journal 2019; 37: 056-063. [DOI:10.1055/s-0039-3400239]
22. Milton N G, Chilumuri A, Rocha-Ferreira E, Nercessian A N, Ashioti M. Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS chemical neuroscience 2012; 3: 706-719. [DOI:10.1021/cn300045d]
23. Moenk M D, Matuszewich L. Juvenile but not adult methamphetamine exposure improves performance in the Morris Water Maze in male rats. Int J Dev Neurosci 2012; 30: 325-331. [DOI:10.1016/j.ijdevneu.2012.01.006]
24. Oishi S, Misu R, Tomita K, Setsuda S, Masuda R, Ohno H, et al. Activation of neuropeptide FF receptors by kisspeptin receptor ligands. ACS Medicinal Chemistry Letters 2011; 2: 53-57. [DOI:10.1021/ml1002053]
25. Park S W, He Z, Shen X, Roman R J, Ma T. Differential action of methamphetamine on tyrosine hydroxylase and dopamine transport in the nigrostriatal pathway of μ-opioid receptor knockout mice. International Journal of Neuroscience 2012; 122: 305-313. [DOI:10.3109/00207454.2011.652319]
26. Patel R, Smith J. Novel actions of kisspeptin signaling outside of GnRH-mediated fertility: a potential role in energy balance. Domestic Animal Endocrinology 2020; 73: 106467. [DOI:10.1016/j.domaniend.2020.106467]
27. Peters M M S, Park C H J, Turner A, Guerin A A, Kim J H. Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates. Addiction Neuroscience 2023: 100064. [DOI:10.1016/j.addicn.2023.100064]
28. Rafaiee R, Ahmadiankia N, Mousavi S A, Jafari B, Kalalian Moghaddam H. Bone marrow mesenchymal stem cells improve cognitive impairments induced by methamphetamine in rats and reduce relapse. Bioimpacts 2023; 13: 97-108. [DOI:10.34172/bi.2022.23329]
29. Rezaeian L, Kalalian-Moghaddam H, Mohseni F, Khaksari M, Rafaiee R. Effects of berberine hydrochloride on methamphetamine-induced anxiety behaviors and relapse in rats. Iran J Basic Med Sci 2020; 23: 1480.
30. Rezayof A, Ghasemzadeh Z, Sahafi O H. Addictive drugs modify neurogenesis, synaptogenesis and synaptic plasticity to impair memory formation through neurotransmitter imbalances and signaling dysfunction. Neurochemistry International 2023: 105572. [DOI:10.1016/j.neuint.2023.105572]
31. Seyedhosseini Tamijani S M, Beirami E, Ahmadiani A, Dargahi L. Effect of three different regimens of repeated methamphetamine on rats’ cognitive performance. Cognitive Processing 2018; 19: 107-115. [DOI:10.1007/s10339-017-0839-0]
32. Shen X, Purser C, Tien L T, Chiu C T, Paul I A, Baker R, et al. μ-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. Journal of neuroscience research 2010; 88: 2294-2302. [DOI:10.1002/jnr.22386]
33. Stauffer C S, Moschetto J M, McKernan S, Meinzer N, Chiang C, Rapier R, et al. Oxytocin-enhanced group therapy for methamphetamine use disorder: Randomized controlled trial. J Subst Abuse Treat. 2020; 116: 108059. [DOI:10.1016/j.jsat.2020.108059]
34. Takino T, Koshikawa N, Miyamori H, Tanaka M, Sasaki T, Okada Y, et al. Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene 2003; 22: 4617-4626. [DOI:10.1038/sj.onc.1206542]
35. Tamijani S M S, Beirami E, Dargahi S, Ahmadiani A, Dargahi L. Neuroprotective effect of thyroid hormones on methamphetamine-induced neurotoxicity via cell surface receptors. Neuroscience Letters 2023; 794: 137009. [DOI:10.1016/j.neulet.2022.137009]
36. Thorn D A, Winter J C, Li J-X. Agmatine attenuates methamphetamine-induced conditioned place preference in rats. European journal of pharmacology 2012; 680: 69-72. [DOI:10.1016/j.ejphar.2012.01.037]
37. Valian N, Ahmadiani A, Dargahi L. Does repeated methamphetamine exposure at different regimens cause parkinsonian-like behavior in rats? Iran JPharm Res 2018; 17: 543.
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.